RxDoctor Payments Data

James Kay, MD

Urology · Evans, GANPI 1679795017

Payments from drug & device makers

$4,652in general payments, 2019–2025

Across 186 payments — averaging $25.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$975
  • Astellas Pharma US Inc$657
  • AbbVie$355
  • Sumitomo Pharma America, Inc.$266
  • Boston Scientific$253
  • Ferring Pharmaceuticals Inc.$221
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,61799%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,652 in reported general payments places this provider in the 50th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$610,464
Medicare patients
1,339
Services billed
13,566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide46$615,275
OrgovyxRelugolix108$277,977
MyrbetriqMirabegron177$130,920
GemtesaVibegron208$117,418
Tamsulosin Hcl915$12,636
Silodosin73$7,696
Mirabegron ErMirabegron15$7,453
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst222$2,227
Alfuzosin Hcl ErAlfuzosin Hcl111$2,126
Finasteride195$2,015
Potassium Citrate ErPotassium Citrate17$1,736
Testosterone Cypionate20$1,241
Doxycycline Hyclate82$1,063
Oxybutynin Chloride ErOxybutynin Chloride44$911
Dutasteride21$670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$146$615,27546 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$266$395,395316 claims
Astellas Pharma US IncMyrbetriq$657$130,920177 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 369 urology providers in Georgia.

Other urology in Evans

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →